Serati Maurizio, Salvatore Stefano, Uccella Stefano, Cardozo Linda, Bolis Pierfrancesco
Department of Obstetrics and Gynecology, University of Insubria, Del Ponte Hospital, Varese, Italy.
Eur Urol. 2009 Mar;55(3):713-9. doi: 10.1016/j.eururo.2008.06.051. Epub 2008 Jun 20.
No authors have investigated whether the administration of local oestrogens in addition to antimuscarinics could have a synergistic effect in the therapy of overactive bladder (OAB).
To compare the efficacy of antimuscarinics alone versus antimuscarinics in combination with local oestrogens for OAB; to verify whether risk factors for lower antimuscarinic efficacy can be overcome by the concomitant use of local oestrogens.
DESIGN, SETTING, AND PARTICIPANTS: Some 229 postmenopausal women with symptomatic urodynamically proven detrusor overactivity were prospectively enrolled at a tertiary level urogynaecology centre and divided into two groups.
Women in group 1 (n=129) were prescribed tolterodine extended release (ER) 4 mg once daily; women in group 2 (n=100) were prescribed both tolterodine ER 4 mg and concomitant oestriol cream application once daily.
All women underwent clinical evaluation and urodynamics in accordance with the Good Urodynamic Practices Guidelines. After 12 wk of treatment the two groups were compared in terms of subjective efficacy for OAB symptom improvement using a three-point scale. Nonresponders were compared to the patients who improved or were cured in order to identify risk factors for resistance to therapy.
There was no significant difference between the two groups in terms of efficacy of therapy: 80.6% in group 1 versus 82% in group 2 (p=0.86). Patients with urodynamically proven detrusor overactivity (DO) occurring during provocative manoeuvres and patients with coital incontinence during orgasm reported a higher failure rate both in the overall study population and in group 2. A possible limitation of the study is the nonrandomised design.
No synergistic effect of local oestrogens and antimuscarinics in the treatment of OAB was found. Antimuscarinic treatment has lower cure rates in women with symptomatic DO complaining of incontinence at orgasm or in patients with DO following provocative manoeuvres. The association of local oestrogens does not influence the role of the two mentioned risk factors.
尚无作者研究除抗毒蕈碱药物外,局部使用雌激素是否能在膀胱过度活动症(OAB)治疗中产生协同作用。
比较单独使用抗毒蕈碱药物与抗毒蕈碱药物联合局部雌激素治疗OAB的疗效;验证局部雌激素的联合使用是否能克服抗毒蕈碱药物疗效较低的风险因素。
设计、地点和参与者:约229名有症状且经尿动力学证实逼尿肌过度活动的绝经后女性前瞻性纳入一家三级泌尿妇科中心,并分为两组。
第1组(n = 129)的女性每天服用一次4mg托特罗定缓释片(ER);第2组(n = 100)的女性每天服用一次4mg托特罗定ER并同时应用雌三醇乳膏。
所有女性均按照良好尿动力学实践指南进行临床评估和尿动力学检查。治疗12周后,使用三点量表比较两组在改善OAB症状方面的主观疗效。将无反应者与改善或治愈的患者进行比较,以确定治疗抵抗的风险因素。
两组在治疗效果方面无显著差异:第1组为80.6%,第2组为82%(p = 0.86)。在激发试验期间经尿动力学证实逼尿肌过度活动(DO)的患者以及在性高潮时出现性交失禁的患者在整个研究人群和第2组中的失败率均较高。本研究的一个可能局限性是非随机设计。
未发现局部雌激素与抗毒蕈碱药物在治疗OAB方面有协同作用。抗毒蕈碱药物治疗在有症状的DO且抱怨性高潮时失禁的女性或激发试验后出现DO的患者中治愈率较低。局部雌激素的联合使用不影响上述两个风险因素的作用。